期刊
NANOMEDICINE
卷 10, 期 24, 页码 3597-3609出版社
FUTURE MEDICINE LTD
DOI: 10.2217/nnm.15.160
关键词
AIDS; cART; HIV; nanomedicine; nanoparticles
资金
- NIH [1R01DA037838-01, 1R01DA027049, 1R21MH101025, R01DA034547-01]
- Herbert Wertheim College of Medicine
- Fundacao para a Ciencia e a Tecnologia, Portugal (FCT) [VIH/SAU/0021/2011, SFRH/BPD/92934/2013]
- FCT/MEC through National Funds
- FEDER [4293]
- NATIONAL INSTITUTE OF MENTAL HEALTH [R21MH101025] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON DRUG ABUSE [R01DA027049, R01DA037838, R01DA034547] Funding Source: NIH RePORTER
Since its discovery almost three decades ago, HIV-1 has grown into the most aggressive pandemic of modern time. Following the implementation of combination antiretroviral therapy, the pathological outcome of HIV infection has substantially improved. However, combination antiretroviral therapy is limited by several factors including, long-term toxicity, serious side effects and complex dosing regimens, and so on. In this regard, researchers have directed their attention toward enhancing current treatment strategies and/or developing alternative HIV-1 therapeutics. In recent years, this attention has fixated on nanomedicine-based anti-HIV therapeutics (HIV-1 nanotherapeutics). In the present study, we have reviewed several HIV-1 nanotherapeutics that have shown success at the preclinical level and/or Phase I/II clinical trials. We also discuss the possible benefits of these nanomedicine-based approaches and their future outlook.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据